NeedleVue™
Diagnostic/Therapeutic
Needle & Tool Guidance
DeepSight’s proprietary NeedleVue™ solution represents a revolutionary advancement in ultrasound-assisted needle guidance technology, poised to redefine a wide spectrum of interventional procedures, ranging from biopsies to drug delivery and regional anesthesia. It addresses the critical demand for accurate localization of minimally invasive devices under ultrasound guidance.
Advantages of NeedleVue include:
- Unparalleled Precision: Achieving confident results by eliminating guesswork and ensuring system that eliminates the need for complicated setups or extensive training
- NeedleVue™ Image Generation: A unique attribute of DeepSight’s NeedleVue Solution is the ability to generate high-resolution ultrasound imaging from the point-of view of the Needle tip or interventional device
- CEUS Compatible: Distinct from traditional systems, NeedleVue operates effectively even when contrast agents are present, offering enhanced versatility in ultrasound imaging applications;
- Versatility: NeedleVue’s omni-directional operation permits maneuverability from any angle, whether within or beyond the ultrasound plane, ensuring consistent tracking. This flexibility extends its utility across a wide range of medical procedures.
NeedleVue will offer a true paradigm shift in the clinicians’ ability to localize a surgical device during freehand procedures with improved tissue biopsy and therapeutic success, leading to lessened patient complications and better health outcomes.
“NeedleVue makes ultrasound procedures an order of magnitude safer. With NeedleVue technology we can move up the learning curve for guided procedures, therefore leveling the field of interventional clinicians.
Absolutely useful to see the needle irrespective of the orientation with the transducer. The problem – with today’s methods – is the deeper you go with the needle, the less the ability you have to see the needle tip. That makes deep biopsies exponentially harder; NeedleVue technology addresses this problem and could take share away from CT guided biopsies.”